Table 3 BII scores at End-of-Study visit for subjects taking Tadalafil or placebo
From: Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies
Study 1 | ||||||
|---|---|---|---|---|---|---|
| Â | Â | 25 th Percentile | Median | 75th Percentile | Mean | SD |
Tadalafil | Baseline | 3.00 | 5.00 | 7.00 | 4.98 | 2.99 |
(n = 125) | End-of-Study | 2.00 | 3.00 | 5.00 | 3.54 | 2.78 |
Placebo | Baseline | 3.00 | 5.00 | 7.00 | 5.21 | 2.73 |
(n = 131) | End-of-Study | 3.00 | 4.00 | 6.00 | 4.46 | 2.78 |
Study 2 | ||||||
| Â | Â | 25 th Percentile | Median | 75th Percentile | Mean | SD |
Tadalafil | Baseline | 3.00 | 5.00 | 7.00 | 4.73 | 2.88 |
(n = 707) | End-of-Study | 1.00 | 3.00 | 5.00 | 3.45 | 2.88 |
Placebo | Baseline | 3.00 | 4.00 | 7.00 | 4.86 | 2.95 |
(n = 187) | End-of-Study | 2.00 | 4.00 | 6.00 | 4.09 | 2.97 |